Formation Bio
Formation Bio is building the AI-native pharma company, applying AI across every stage of drug development to bring more medicines to patients faster and more efficiently.
Challenge
How could Formation Bio translate its vision into sustained media momentum that would help position the company as the definitive leader in AI-driven drug development and attract the deal flow, talent, and credibility needed to scale its pipeline?
Approach
Formation Bio partnered with Thermal to execute high-impact communications that would demonstrate the company’s differentiated model in action. Together, we:
-
- Orchestrated high-visibility transaction announcements: Secured exclusive Endpoints News coverage for Formation Bio’s licensing deal with IMIDomics. Coordinated video production, media prep, and strategic messaging to reinforce Formation’s hub-and-spoke model and position the company as a new category of partner for stranded biotech assets.
- Built sustained industry visibility through awards and thought leadership: Developed award submissions that secured Endpoints 11 recognition and positioned the company for Fierce 15 and BioSpace 40 Under 40, ensuring consistent visibility with pharma business development and investment decision-makers.
- Established strategic communications infrastructure: Developed Formation’s PR roadmap, messaging frameworks, and media relations strategy to support the company’s evolution from newly-funded startup to industry thought leader.
Impact
Through our partnership, Formation Bio has:
-
- Secured tier-one industry coverage including exclusive Endpoints News features on key business development milestones, reinforcing Formation’s positioning as the ideal partner for companies with promising assets facing capital or time constraints.
- Built sustained visibility with key audiences through strategic awards recognition including Endpoints 11, establishing Formation Bio as one of biotech’s most exciting and promising startups.
- Created scalable communications infrastructure including comprehensive PR roadmaps, messaging architecture, and media relations frameworks supporting Formation’s growth toward a portfolio of drug assets.
“The bottleneck isn’t discovering interesting drugs, its testing. That’s where the cost and time is the greatest. The one competitive advantage you want to build a pharma company around is not in discovery. It’s actually in drug development and clinical trials.”
Benjamine Liu – CEO of Formation Bio
